June 8, 2009
The angiotensin receptor blocker (ARB) valsartan did not significantly reduce either primary end point in GISSI-AF; that is, time to the first recurrence of atrial fibrillation (AF) or the proportion of patients with one or more episodes of AF during the one-year follow-up period.
Log in or Register now.
Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.